Announcement on Withdrawal of Drug Registration Application by Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Withdrawal of Drug Registration Application by Subsidiary
Filed with SSE · · 2 pages · Chinese
Release
Humanwell Healthcare (Group) Co.,Ltd. on 6ix
Earlier from Humanwell Healthcare (Group) Co.,Ltd
- Announcement on Participation in Investment for Establishing Private Equity Fund and Related Party Transaction
- Announcement on Initiation of Phase II Clinical Trial for HW231019 Tablets
- Announcement on Pledge of Partial Shares of Controlling Shareholder
- Announcement on HWH217 Tablets Obtaining Notice of Approval for Drug Clinical Trials
- Announcement on Pregabalin Sustained Release Tablets Obtaining Notice of Approval for Drug Clinical Trials
Later from Humanwell Healthcare (Group) Co.,Ltd
- Announcement on Resolutions of the 4th Meeting of the 11th Board of Directors
- Announcement on Obtaining Marketing Authorization from the German Federal Institute for Drugs and Medical Devices (BfArM) for Midazolam Injection
- Announcement on Receiving the Notice in Advance of Administrative Penalty from Hubei Securities Regulatory Bureau of China Securities Regulatory Commission
- Announcement on HW252001 Tablets Obtaining Notice of Approval for Drug Clinical Trials
- Indicative Announcement on the Results of Controlling Shareholder's Share Increase and Equity Change Reaching 1% Scale
Follow Humanwell Healthcare (Group) Co.,Ltd into a list and get an email when it puts out news.
Follow Humanwell Healthcare (Group) Co.,Ltd